PharmNovo AB announces that the drug product for its lead candidate PN6047 has been manufactured for the upcoming Phase IIa proof-of-concept (PoC) study in neuropathic pain.PharmNovo is a ...

Morning yoga enhances sleep quality and well-being more than evening sessions, according to a randomised controlled trial ...

The FDA has agreed on the design of two randomized phase 3 trials evaluating CRB-701, a next-generation Nectin-4-targeted ...

Strong participation in recent $33 million common stock offering highlights investor confidence in late-stage clinical momentum and commercial ...

New evidence links viral infections to dementia risk, suggesting vaccines and antiviral therapies may offer preventive ...

TAMPA, Fla., April 7, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to ...

Can exercise replace ADHD medication? A new study reveals that integrated cognitive-motor exercise significantly improves inhibitory control and working memory in children aged 6–10.

Organogenesis Holdings Inc. looks undervalued at distressed multiples; new DFU RCT data supports coverage despite 2026 CMS ...

Organogenesis Holdings Inc. (NASDAQ:ORGO) shares surged about 20% on Tuesday after the company reported that its PuraPly AM ...

Organogenesis Holdings Inc. ORGO shares are up during Tuesday’s premarket session following the company’s announcement of achieving the primary endpoint in a randomized controlled trial evaluating ...

The presentations will showcase new preclinical and clinical data supporting EscharEx’s differentiated mechanism of action, clinical performance, and advancement of its ongoing Phase III development ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated ...